Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

NCT01872182 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Abdominal Obesity Metabolic Syndrome

Interventions

DRUG: ALS-L1023
DRUG: placebo

Sponsor

Hanmi Pharmaceutical Company Limited